Evaluating Ki-67 and Apoptosis in Breast Cancer Treatment
Author Information
Author(s): Burcombe Russell, Wilson George D, Dowsett Mitch, Khan Ifty, Richman Paul I, Daley Frances, Detre Simone, Makris Andreas
Primary Institution: Kent Oncology Centre, Maidstone Hospital
Hypothesis
Can early changes in Ki-67 and apoptotic index predict clinical or pathological response to neoadjuvant chemotherapy in breast cancer patients?
Conclusion
Early changes in biological marker expression during chemotherapy do not reliably predict clinical or pathological response.
Supporting Evidence
- 56% of patients showed a clinical response to treatment.
- 68% of patients had a reduction in Ki-67 index at day 21.
- 31% achieved a pathological response by histological criteria.
- Increased day-21 AI was a statistically significant predictor of pathological response.
Takeaway
Doctors are trying to figure out if measuring certain markers in breast cancer can help predict how well treatment will work, but so far, it’s not clear if they can.
Methodology
Patients received neoadjuvant FEC chemotherapy and underwent repeat core biopsies to analyze Ki-67 and apoptotic index at different treatment stages.
Potential Biases
Potential sampling error and intra-tumor variability in biopsies may affect results.
Limitations
The study had a small sample size and lacked complete pathological responders, limiting the ability to draw definitive conclusions.
Participant Demographics
The study included 27 female patients with operable invasive primary breast carcinoma, with 52% pre-menopausal and varying tumor grades.
Statistical Information
P-Value
p = 0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website